<p> Vivek Daniel Paul has over 18 years of research experience in driving the discovery and development of therapeutic bacteriophages and bacteriophage-based protein antibacterial agents called ectolysins. Along with his colleagues, he discovered the ectolysin P128, a potent anti-Staphylococcal agent. </p>

<p> Mr. Paul joined GangaGen in 2002 and later moved to Syngene International in 2009, where he worked as a scientist delivering biology R & D projects for multinational pharmaceutical companies. Before returning to GangaGen in 2013, he worked as a research scholar in Prof. Alan Davidson’s lab at University of Toronto where he got trained in structural and biophysical aspects of protein-protein interaction and macromolecular assembly in the context of phage morphogenesis.</p>

<p> Mr. Paul received his Master’s degree in Biochemistry from Bharathiar University, Tamil Nadu. He has several patents in the field of phage ectolysins and has published in peer-reviewed journals.</p>